Search Results - "Jacob, Juby"

Randomized control trial on impact of clinical pharmacist led interventions on antibiotic stewardship program in children 0 to 18 years age in a tertiary care hospital in southern India by Unni, Jeeson C., Chacko, Manas, Jacob, Juby, Warrier, Anup

“…A prospective randomized controlled interventional study was conducted at a quaternary care multispecialty hospital in South India with the primary objective…”
Get full text

Assessment of dupilumab in children with moderate‐to‐severe type 2 asthma with or without evidence of allergic asthma by Papadopoulos, Nikolaos G., Szefler, Stanley J., Bacharier, Leonard B., Maspero, Jorge F., Domingo, Christian, Fiocchi, Alessandro, Lee, Jason K., Daizadeh, Nadia, Lederer, David J., Hardin, Megan, Gall, Rebecca, Djandji, Michel, Siddiqui, Shahid, Jacob‐Nara, Juby A., Deniz, Yamo, Rowe, Paul J.

“…Background Cytokines, such as interleukins (IL)‐4/5/13, play a key role in multiple type 2 inflammatory diseases, including allergic asthma. Dupilumab, a human…”
Get full text

Targeting Type 2 Inflammation and Epithelial Alarmins in Chronic Obstructive Pulmonary Disease: A Biologics Outlook by Rabe, Klaus F, Rennard, Stephen, Martinez, Fernando J, Celli, Bartolome R, Singh, Dave, Papi, Alberto, Bafadhel, Mona, Heble, Jigna, Radwan, Amr, Soler, Xavier, Jacob Nara, Juby A, Deniz, Yamo, Rowe, Paul J

“…Chronic obstructive pulmonary disease (COPD) is a complex, heterogeneous, progressive inflammatory airway disease associated with a significant impact on…”
Get full text

Dupilumab improves long‐term outcomes in patients with uncontrolled, moderate‐to‐severe GINA‐based type 2 asthma, irrespective of allergic status by Rabe, Klaus F., Pavord, Ian D., Busse, William W., Chupp, Geoffrey L., Izuhara, Kenji, Altincatal, Arman, Gall, Rebecca, Pandit‐Abid, Nami, Deniz, Yamo, Rowe, Paul J., Jacob‐Nara, Juby A., Radwan, Amr

“…Background Previous research has shown greater efficacy of dupilumab in patients with uncontrolled asthma and type 2 inflammation. We analyzed dupilumab's…”
Get full text

Dupilumab sustains efficacy in patients with moderate-to-severe type 2 asthma regardless of inhaled corticosteroids dose by Pavord, Ian D, Bourdin, Arnaud, Papi, Alberto, Domingo, Christian, Corren, Jonathan, Altincatal, Arman, Radwan, Amr, Pandit-Abid, Nami, Jacob-Nara, Juby A, Deniz, Yamo, Rowe, Paul J, Laws, Elizabeth, Lederer, David J, Hardin, Megan

“…Dupilumab, a human monoclonal antibody, blocks the shared receptor component for interleukins-4/13, key and central drivers of type 2 inflammation. The…”
Get full text

Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate‐to‐severe type 2 asthma by Papi, Alberto, Corren, Jonathan, Castro, Mario, Domingo, Christian, Rogers, Linda, Chapman, Kenneth R., Jackson, Daniel J., Daizadeh, Nadia, Pandit‐Abid, Nami, Gall, Rebecca, Jacob‐Nara, Juby A., Rowe, Paul J., Deniz, Yamo, Ortiz, Benjamin

“…Background Severe asthma exacerbations increase the risk of accelerated lung function decline. This analysis examined the effect of dupilumab on forced…”
Get full text

Efficacy of dupilumab in patients with uncontrolled, moderate‐to‐severe asthma with fungal sensitization by Corren, Jonathan, Hanania, Nicola A., Busse, William W., Sher, Lawrence D., Altincatal, Arman, Hardin, Megan, Mannent, Leda P., Amin, Nikhil, Lederer, David J., Soler, Xavier, Jacob‐Nara, Juby A., Rowe, Paul J., Deniz, Yamo

“…Abstract Background Fungal sensitization (FS) exacerbates asthma in patients who have elevated type 2 inflammatory response. Dupilumab, a fully human…”
Get full text

Dupilumab efficacy across serum IgE and blood eosinophil levels in chronic rhinosinusitis with nasal polyposis by Bachert, Claus, Gevaert, Philippe, Lipworth, Brian, Mustafa, Syed Shahzad, Lane, Andrew P., Mullol, Joaquim, Rowe, Paul, Deniz, Yamo, Kamat, Siddhesh, Khan, Asif H., Jacob‐Nara, Juby, Siddiqui, Shahid, Ruddy, Marcella, Laws, Elizabeth, Msihid, Jérôme, Harel, Sivan, Jagerschmidt, Alexandre, Amin, Nikhil, Mannent, Leda, Rout, Raj

Get full text

Prevalence of type 2 inflammatory signatures and efficacy of dupilumab in patients with chronic rhinosinusitis with nasal polyps from two phase 3 clinical trials: SINUS‐24 and SINUS‐52 by Bachert, Claus, Khan, Asif H., Lee, Stella E., Hopkins, Claire, Peters, Anju T., Fokkens, Wytske, Praestgaard, Amy, Radwan, Amr, Nash, Scott, Jacob‐Nara, Juby A., Deniz, Yamo, Rowe, Paul J.

“…Background This post hoc analysis of the international SINUS‐24/‐52 trials (NCT02912468/NCT02898454) aimed to assess dupilumab efficacy in patients with severe…”
Get full text

Dupilumab 200 mg was efficacious in children (6–11 years) with moderate‐to‐severe asthma for up to 2 years: EXCURSION open‐label extension study by Phipatanakul, Wanda, Vogelberg, Christian, Bacharier, Leonard B., Dell, Sharon, Altincatal, Arman, Gall, Rebecca, Ledanois, Oliver, Sacks, Harry, Jacob‐Nara, Juby A., Deniz, Yamo, Rowe, Paul J.

“…Background The phase 3 VOYAGE (NCT02948959) and open‐label extension EXCURSION (NCT03560466) studies evaluated dupilumab in children (6–11 years) with…”
Get full text

Improvement in patient‐reported “taste” and association with smell in dupilumab‐treated patients with severe chronic rhinosinusitis with nasal polyps from the SINUS‐24 and SINUS‐52 trials by Peters, Anju T., Soler, Zachary M., Kern, Robert C., Heffler, Enrico, Maspero, Jorge F., Crampette, Louis, Fujieda, Shigeharu, Lane, Andrew P., Zhang, Haixin, Nash, Scott, Khan, Asif H., Siddiqui, Shahid, Jacob‐Nara, Juby A., Rowe, Paul, Deniz, Yamo

Get full text

The IL-4-IL-4Rα axis modulates olfactory neuroimmune signaling to induce loss of smell by Hara, Yannis, Jha, Mithilesh Kumar, Huang, Jeremy Y, Han, Yingnan, Langohr, Ingeborg M, Gaglia, Giorgio, Zhu, Cheng, Piepenhagen, Peter, Gayvert, Kaitlyn, Lim, Wei Keat, Asrat, Seblewongel, Nash, Scott, Jacob-Nara, Juby A, Orengo, Jamie M, Bangari, Dinesh S, de Rinaldis, Emanuele, Mattoo, Hamid, Hicks, Alexandra

“…IL-4 and IL-13 have non-redundant effects in olfaction, with loss of smell in mice evoked only by intranasal administration of IL-4, but not IL-13. IL-4-evoked…”
Get full text

Responder analysis to demonstrate the effect of targeting type 2 inflammatory mechanisms with dupilumab across objective and patient‐reported endpoints for patients with severe chronic rhinosinusitis with nasal polyps in the SINUS‐24 and SINUS‐52 studies by Bachert, Claus, Peters, Anju T., Heffler, Enrico, Han, Joseph K., Olze, Heidi, Pfaar, Oliver, Chuang, Chien‐Chia, Rout, Raj, Attre, Richa, Goga, Ledia, Jacob‐Nara, Juby A., Rowe, Paul J., Deniz, Yamo, Chen, Zhen, Kamat, Siddhesh, Siddiqui, Shahid

“…The involvement of multiple disease domains in CRSwNP requires assessment of a variety of clinical endpoints, however, analyses of within‐patient response…”
Get full text

Impact of Dupilumab on Sinonasal Symptoms and Outcomes in Severe Chronic Rhinosinusitis With Nasal Polyps by Hopkins, Claire, Mullol, Joaquim, Khan, Asif H., Lee, Stella E., Wagenmann, Martin, Hellings, Peter, Fokkens, Wytske, Msihid, Jérôme, Nair, Radhika, Kamat, Siddhesh, Nash, Scott, Radwan, Amr, Jacob‐Nara, Juby A., Deniz, Yamo, Rowe, Paul J.

“…Objectives To assess the severity of the top 5 22‐item Sino‐Nasal Outcome Test (SNOT‐22) items ranked most important by patients with chronic rhinosinusitis…”
Get full text

Efficacy of dupilumab in patients with uncontrolled, moderate-to-severe asthma recruited from Japanese centers in the phase 3 LIBERTY ASTHMA TRAVERSE study by Tohda, Yuji, Nakamura, Yoichi, Fujisawa, Takao, Ebisawa, Motohiro, Msihid, Jerome, Djandji, Michel, Ortiz, Benjamin, Jacob-Nara, Juby A., Deniz, Yamo, Rowe, Paul J., Ishida, Masato, Arima, Kazuhiko

“…Safety and efficacy data for dupilumab beyond 1 year are lacking for patients from Japan with moderate-to-severe asthma. The TRAVERSE open-label extension…”
Get full text

Dupilumab pharmacokinetics and effect on type 2 biomarkers in children with moderate-to-severe asthma by Jackson, Daniel J., Bacharier, Leonard B., Phipatanakul, Wanda, Sher, Lawrence, Domingo, Christian, Papadopoulos, Nikolaos, Modena, Brian, Li, Ning, Xia, Changming, Kamal, Mohamed A., Dillon, Myles, Wolfe, Kelley, Gall, Rebecca, Amin, Nikhil, Mannent, Leda P., Laws, Elizabeth, Rowe, Paul J., Jacob-Nara, Juby A., Deniz, Yamo, Lederer, David J., Hardin, Megan, Xu, Christine

“…Type 2 inflammation is common in children with asthma. Dupilumab, a human antibody, blocks the signaling of interleukin -4 and -13, key and central drivers of…”
Get full text

Dupilumab efficacy in subgroups of type 2 asthma with high-dose inhaled corticosteroids at baseline by Bourdin, Arnaud, Virchow, J. Christian, Papi, Alberto, Lugogo, Njira L., Bardin, Philip, Antila, Martti, Halpin, David M.G., Daizadeh, Nadia, Djandji, Michel, Ortiz, Benjamin, Jacob-Nara, Juby A., Gall, Rebecca, Deniz, Yamo, Rowe, Paul J.

“…Dupilumab blocks the shared receptor component for interleukin (IL)-4/IL-13, key and central drivers of type 2 inflammation in multiple diseases. In phase 3…”
Get full text

The interleukin-4/interleukin-13 pathway in type 2 inflammation in chronic rhinosinusitis with nasal polyps by Bachert, Claus, Hicks, Alexandra, Gane, Simon, Peters, Anju T, Gevaert, Philippe, Nash, Scott, Horowitz, Julie E, Sacks, Harry, Jacob-Nara, Juby A

“…Chronic rhinosinusitis with nasal polyps (CRSwNP) is predominantly a type 2 inflammatory disease associated with type 2 (T2) cell responses and epithelial…”
Get full text

Rapid and sustained effects of dupilumab in severe chronic rhinosinusitis with nasal polyps by Hellings, Peter W., Peters, Anju T., Chaker, Adam M., Heffler, Enrico, Zhang, Haixin, Praestgaard, Amy, Nash, Scott, Khan, Asif H., Siddiqui, Shahid, Jacob‐Nara, Juby A., Rowe, Paul J., Deniz, Yamo

Get full text

Dupilumab efficacy and biomarkers in chronic rhinosinusitis with nasal polyps: Association between dupilumab treatment effect on nasal polyp score and biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps in the phase 3 SINUS‐24 and SINUS‐52 trials by Bachert, Claus, Corren, Jonathan, Lee, Stella E., Zhang, Haixin, Harel, Sivan, Cunoosamy, Danen, Khan, Asif H., Jacob‐Nara, Juby A., Siddiqui, Shahid, Nash, Scott, Rowe, Paul J., Deniz, Yamo

Get full text